Search Blog
Categories
January 2018
M T W T F S S
« Dec    
1234567
891011121314
15161718192021
22232425262728
293031  

Tags

American Manganese Discusses Plans for 2018 and Reviews 2017

American Manganese Discusses Plans for 2018 and Reviews 2017

Vancouver, British Columbia (FSCwire) – Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. (“American Manganese” or “AMI” or the “Company”), (TSX.V: AMY; Pink Sheets: AMYZF; Frankfurt: 2AM), is pleased to describe its goals for 2018 and review the company’s activities and accomplishments from 2017. The company will continue its aggressive research and development programs for its patent pending recycling opportunity by building a 1 kg/hour pilot plant utilizing Lithium Ion Battery scraps as feedstock.

2018 (current price Cobalt $77,000/tonne)

The Company’s goals for this year include:

  • Kemetco to commence the bench scale test work for new IP’s to be patented and incorporated into the new pilot plant design and construction.
  • Build a 1 kg/hour pilot plant, and procure battery scraps as feed stock for pilot plant testing.
  • Investigate contracting a research/engineering study for developing an automated disassembly process for lithium ion batteries.
  • Seeking a partner to fund the ongoing work.
  • Complete the necessary research for filing two to three additional patents which were recognized last year. These additional patents will strengthen AMI’s IP position and create opportunities for recovering other valuable materials which the company aims to capitalize on.
  • Complete a business plan which got underway in December 2017.

2017 – Review

AMI has accomplished all their 2017 commitments on time and on budget. The company completed bench scale tests resulting in recoveries of 100% for all commonly used cathode metals, Lithium, Cobalt, Nickel, Aluminum and Manganese. Cathode materials were recycled from commonly used battery chemistries including: Lithium Cobalt (LiCo), Lithium Nickel Manganese Cobalt (LiNMC), Lithium Nickel Manganese Aluminum (LNMA) and Lithium Manganese Oxide (LMO). Kemetco successfully built a working prototype button cell rechargeable battery from recycled cathode materials for the above chemistries.

AMI has filed for a US Patent on November 10, 2017 to protect its Intellectual LIB Battery Recycling process.

2017 was a pivotal year for AMI’s recycling opportunity where recognition of the potential viability of their process is being recognized within the lithium ion battery community.

American Manganese raised $1,193,000 during the year to carry out the above work. Since August of 2016 American Manganese’s market capital has increased from about $2 to about forty $40 million dollars.

AMI received federal research funding from IRAP in early 2017.

During 2017 AMI’s patent pending recycling technology has received international exposure from international publications such as Bloomberg Financial, Thompson Reuters and several national and international recycling publications. Also, the company was invited to present their process at NAATBatt battery recycling workshop in Ann Arbor, Michigan, the Cobalt Conference in Marrakech, Morocco and the 22nd International Congress Battery Recycling Conference in Lisbon, Portugal.

In December, Mr. Reaugh was invited by Bloomberg Financial to be a panelist on Electric Vehicle Battery material and the Electric vehicle supply chain and its inaugural “The Future of Mobility Summit” at the Four Seasons Hotel Silicon Valley in Palo Alto, California, February 2, 2018.

On December 28, 2017 the Company entered into a joint-venture agreement with the Australian miner Longford Resources. Longford may earn a 60% interest in the Rocher Deboule Copper Gold Cobalt Property by expending $2,000,000 two million on exploration over four years. The Company and shareholders will benefit from any significant discoveries Longford may make.

The Company has added to the value of intellectual property while de-risking its patent pending process.

About American Manganese Inc.

American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries.

Interest in the Company’s patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become the industry leader in recycling spent electric vehicle lithium ion batteries and recovering 100% of the cathode metals such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, Lithium-Cobalt- Aluminum and Lithium-Manganese (Please see the Company’s July 27, 2017 press release for further details).

On behalf of Management

AMERICAN MANGANESE INC.

Larry W. Reaugh

President and Chief Executive Officer

Information Contacts:

Larry W. Reaugh

President and Chief Executive Officer

Telephone: 778 574 4444; Email: lreaugh@amymn.com

www.americanmanganeseinc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward –looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

To view this press release as a PDF file, click onto the following link:

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire

American Manganese Discusses Plans for 2018 and Reviews 2017

By American Manganese Inc.

VANCOUVER, BC / ACCESSWIRE / January 19, 2018 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. (“American Manganese” or “AMI” or the “Company”), (TSX-V: AMY; OTC PINK: AMYZF; FSE: 2AM), is pleased to describe its goals for 2018 and review the company’s activities and accomplishments from 2017. The company will continue its aggressive research and development programs for its patent-pending recycling opportunity by building a 1 kg/hour pilot plant utilizing Lithium-Ion Battery scraps as feedstock.

2018 (current price Cobalt $77,000/tonne)

The Company’s goals for this year include:

  • Kemetco to commence the bench scale test work for new IP’s to be patented and incorporated into the new pilot plant design and construction.
  • Build a 1 kg/hour pilot plant, and procure battery scraps as feed stock for pilot plant testing.
  • Investigate contracting a research/engineering study for developing an automated disassembly process for lithium-ion batteries.
  • Seeking a partner to fund the ongoing work.
  • Complete the necessary research for filing two to three additional patents which were recognized last year. These additional patents will strengthen AMI’s IP position and create opportunities for recovering other valuable materials which the company aims to capitalize on.
  • Complete a business plan which got underway in December 2017.

2017 – Review

AMI has accomplished all their 2017 commitments on time and on budget. The company completed bench scale tests resulting in recoveries of 100% for all commonly used cathode metals, Lithium, Cobalt, Nickel, Aluminum and Manganese. Cathode materials were recycled from commonly used battery chemistries including: Lithium Cobalt (LiCo), Lithium Nickel Manganese Cobalt (LiNMC), Lithium Nickel Manganese Aluminum (LNMA) and Lithium Manganese Oxide (LMO). Kemetco successfully built a working prototype button cell rechargeable battery from recycled cathode materials for the above chemistries.

AMI has filed for a US Patent on November 10, 2017 to protect its Intellectual LIB Battery Recycling process.

2017 was a pivotal year for AMI’s recycling opportunity where recognition of the potential viability of their process is being recognized within the lithium ion battery community.

American Manganese raised $1,193,000 during the year to carry out the above work. Since August of 2016 American Manganese’s market capital has increased from about $2 to about forty $40 million dollars.

AMI received federal research funding from IRAP in early 2017.

During 2017 AMI’s patent pending recycling technology has received international exposure from international publications such as Bloomberg Financial, Thompson Reuters and several national and international recycling publications. Also, the company was invited to present their process at NAATBatt battery recycling workshop in Ann Arbor, Michigan, the Cobalt Conference in Marrakech, Morocco and the 22nd International Congress Battery Recycling Conference in Lisbon, Portugal.

In December, Mr. Reaugh was invited by Bloomberg Financial to be a panelist on Electric Vehicle Battery material and the Electric vehicle supply chain and its inaugural “The Future of Mobility Summit” at the Four Seasons Hotel Silicon Valley in Palo Alto, California, February 2, 2018.

On December 28, 2017 the Company entered into a joint-venture agreement with the Australian miner Longford Resources. Longford may earn a 60% interest in the Rocher Deboule Copper Gold Cobalt Property by expending $2,000,000 two million on exploration over four years. The Company and shareholders will benefit from any significant discoveries Longford may make.

The Company has added to the value of intellectual property while de-risking its patent pending process.

About American Manganese Inc.

American Manganese Inc. is a diversified specialty and critical metal company focused on capitalizing on its patented intellectual property through low cost production or recovery of electrolytic manganese products throughout the world, and recycling of spent electric vehicle lithium ion rechargeable batteries.

Interest in the Company’s patented process has adjusted the focus of American Manganese Inc. toward the examination of applying its patented technology for other purposes and materials. American Manganese Inc. aims to capitalize on its patented technology and proprietary know-how to become the industry leader in recycling spent electric vehicle lithium ion batteries and recovering 100% of the cathode metals such as: Lithium-Cobalt, Lithium-Cobalt-Nickel-Manganese, Lithium-Cobalt- Aluminum and Lithium-Manganese (Please see the Company’s July 27, 2017 press release for further details).

On behalf of Management

AMERICAN MANGANESE INC.

Larry W. Reaugh
President and Chief Executive Officer

Information Contacts:

Larry W. Reaugh
President and Chief Executive Officer
Telephone: 778 574 4444; Email: lreaugh@amymn.com

www.americanmanganeseinc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

SOURCE: American Manganese Inc.

ReleaseID: 486387

Wired News – Tiffany & Co. Reported Strong Holiday Season Sales; Shared Guidance for FY17 and Early Forecasts for FY18

By Active-Investors

Stock Monitor: Signet Jewelers Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Tiffany & Co. (NYSE: TIF) (“Tiffany”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TIF as the Company’s latest news hit the wire. On January 17, 2018, the Company disclosed that its net global sales witnessed an increase of 8% to $1.05 billion during the holiday months of November and December 2017. The Company has attributed the increase in sales to the growth across geographies, product lines, and increase in store sales by 5%. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Signet Jewelers Limited (NYSE: SIG), which also belongs to the Services sector as the Company Tiffany. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SIG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Tiffany most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=TIF

The Company’s overall worldwide net sales increased by 6% and global store sales witnessed an increase of 3%. The increase in sales during the holiday season has led to the Company’s management to up its annual earnings forecast for the year ending January 31, 2018 (fiscal 2017). Additionally, the Company has also shared the preliminary earnings outlook for fiscal 2018.

Commenting on the Company’s improved sales performance, Alessandro Bogliolo, CEO of Tiffany, said:

“While our major Fashion Jewelry collections continued to perform well, customers were equally excited about our Fine Jewelry, our Watches and our new Home and Accessories collection. Some exceptional High Jewelry creations further contributed to the sales performance. This recent return to growth in worldwide comparable store sales, fueled by a substantial improvement in the Americas and Asia Pacific, is consistent with our commitment to generate solid and sustainable growth in sales, operating margin and earnings that is at least comparable to our industry peers over the long-term.”

The Company believes that the decline in store sales in the recent quarters could be stemmed by evolving their product lines, improving customer experience and by increasing strategic business-related spending. The Company’s preliminary outlook for fiscal 2018 reflects these points. He also reiterated the fact that increase in sales reflected the strength of Tiffany’s brand and that the Company plans to leverage this fact to expand its global footprint and seize various long-term global opportunities.

Key Highlights of Holiday Season Sales

  • The Company’s total Americas based sales witnessed an increase of 7%, or $516 million, and its store sales increased by 6%. Although the Company’s sales witnessed an increase across the US, Canada, and Latin America, the increase in sales was more from its US market.
  • Total sales from Asia/Pacific increased by 16%, or $232 million. The increase was mainly due to an increase of 7% store sales, opening on new stores and increase in wholesale sales. The Company shared that most of spending in this region was seen by customers in mainland China, Hong Kong, and Korea.
  • The Company’s sales in Japan increased by 1%, or 145 million, while the store sales remained the same.
  • In Europe, the Company’s sales increased by 14%, or 136 million. The increase was due to the opening of new stores, this, however, had a slightly negative impact on the overall store sales which rose by 2%.
  • The Company’s other total sales witnessed a decline of 10%, or $18 million, and a 14% increase in store sales, which was offset by a decline in wholesale sales of diamonds.
  • The Company had 316 stores operational as on December 31, 2017, of which there are 125 stores in the Americas, 87 stores in Asia/Pacific, 54 stores in Japan, 46 stores in Europe, and 4 stores in the UAE. The products in the High, Fine and Solitaire and the Fashion jewelry categories witnessed the maximum sales, while the Engagement Jewelry and Wedding Bands category witnessed a marginal growth.

Revised Guidance for Fiscal 2017

The Company has revised its guidance for fiscal year 2017, some of the key points include:

  • Increase in global net sales by approximately 4% compared to fiscal 2016;
  • Increase in diluted net earnings per share (EPS) in double digits as compared to diluted net EPS of $3.55 in fiscal 2016;
  • The Company expects that the re-measurement and deemed repatriation tax will result in aggregate charges of $115 million to $165 million in Q4 2017 ending January 31, 2018. The amount in an estimate and not final and can change later. (The Company’s guidance for fiscal 2017 assumes that its global retail square footage increases by 2%; its operating margins are more than fiscal 2016; interest and other expenses, net of $35 million to $37 million; income tax rate is approximately 33%; no major changes in exchange rates; and minimal benefit to net diluted EPS from share buybacks. These do not include impact of recent changes in tax-code);
  • Net cash from operations to be at least $735 million;
  • Free cash flows of more than $500 million (the cash flow guidance is based on the Company’s assumption that the growth rate of net is same as sales growth, capital expenditures of $235 million and that the net earnings as per the Company’s expectations).

Preliminary Guidance for fiscal 2018

For the fiscal 2018 the Company expects:

  • Increase in global sales in mid-single-digit percentage;
  • Increased business spending in technology, marketing communications, visual merchandising, digital, and store presentations for achieving sales, margin and earnings growth objectives;
  • Marginal declined in net diluted EPS compared to net diluted EPS of FY17 due to increase in business spending;
  • To benefit from the implementation of the new tax-code.

The Company plans to provide a detailed guidance for 2018 in March 2018 when it will report the results for full fiscal year 2017.

About Tiffany & Co.

New York-based Tiffany has been in existence since 1837 and is a holding Company that operates through its subsidiary companies. Its main subsidiary Tiffany and Co., is a leading high-end and luxury jeweler and specialty retailer. Its product offerings include jewelry, timepieces, sterling silverware, china, crystal, stationery, fragrances and accessories. The holding Company through Tiffany and Co. and other subsidiaries are engaged in product design, manufacturing and retailing activities.

Tiffany has a global presence with over 300 stores and over 11,900 employees.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, Tiffany’s stock slightly declined 0.86%, ending the trading session at $108.05.

Volume traded for the day: 1.93 million shares, which was above the 3-month average volume of 1.43 million shares.

Stock performance in the last month – up 6.62%; previous three-month period – up 13.81%; past twelve-month period – 35.16%; and year-to-date – up 3.94%

After yesterday’s close, Tiffany’s market cap was at $13.45 billion.

Price to Earnings (P/E) ratio was at 28.97.

The stock has a dividend yield of 1.85%.

The stock is part of the Services sector, categorized under the Jewelry Stores industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486400

Free Research Report as Shaw Communications’ Revenue Grew 2.7%; EPS Surged 22.2%

By Active-Investors

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free earnings report on Shaw Communications Inc. (NYSE: SJR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SJR. Shaw Communications reported its first quarter fiscal 2018 operating and financial results on January 11, 2018. The communications and media Company’s top- and bottom-line numbers fell short of market expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Shaw Communications most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=SJR

Earnings Highlights and Summary

For the quarter ended November 30, 2017. Shaw Communications’ consolidated revenue increased 2.7% to C$1.25 billion compared to C$1.22 billion in Q1 FY17, driven by continued strong performance in Wireless, Consumer Internet and Business. The Company’s reported numbers fell short of analysts’ estimates by C$10 million.

During Q1 FY18, Shaw Communications’ operating income fell 4.6% to C$481 million compared to C$504 million in Q1 FY17. The Company’s operating margin for the reported quarter fell 2.9 points to 38.5% compared to 41.4% in the year ago same period.

Shaw Communications’ net income was C$114 million, or C$0.22 per share, for Q1 FY18 compared to C$89 million, or C$0.18 per diluted share, in Q1 FY17. The increase in earnings reflected a prior period non-operating loss partially offset by lower operating income from continuing operations and higher income taxes in the reported quarter. The Company’s earnings lagged behind Wall Street’s estimates of C$0.06 per share.

Operating Results

During Q1 FY18, Shaw Communications’ Wireless revenue and operating income before restructuring costs and amortization of C$175 million and C$35 million improved 26.8% and 16.7% respectively on a y-o-y basis. The improvement in Wireless results was primarily attributed to an increase of approximately 130,000 subscribers in the past year to nearly 1.2 million at the end of the reported quarter.

In Q1 FY18, Shaw Communications added approximately 34,000 Wireless subscribers, a significant increase from the 9,500 net additions achieved in Q1 FY17. The increase in the customer base reflected the ongoing execution of the Company’s wireless growth strategy to improve the network and customer experience.

For Q1 FY18, Shaw Communications’ Wireline revenue and operating income before restructuring costs and amortization of C$1.08 billion and C$446 million decreased 0.4% and 5.9%, respectively. The y-o-y decline in Wireline results was driven primarily by Consumer video flow through of promotions that were initiated in H2 FY17. The reported quarter also reflected increased levels of planned corporate costs relative to the comparable period.

In the reported quarter, Shaw Business posted revenue of C$140 million, representing a 6.1% y-o-y improvement. Growth in Business was primarily related to market share gains in the small and medium-sized businesses driven by the Smart suite of products, now including Smart Surveillance which launched in December 2017.

Shaw Communications’ Wireline subscribers declined by approximately 34,000 in Q1 FY18 compared to a loss of approximately 30,000 in Q1 FY17. The Company noted that continued strong Internet gains of over 17,000 in the period were more than offset by video, phone, and higher seasonal satellite losses.

Cash Matters

Shaw Communications’ free cash flow for Q1 FY18 was C$51 million, compared to C$158 million in Q1 FY17. The decrease in free cash flow in the reported quarter was largely due to planned higher capital spending and lower operating income before restructuring costs and amortization.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, Shaw Communications’ stock slightly fell 0.41%, ending the trading session at $21.65.

Volume traded for the day: 519.38 thousand shares.

Stock performance in the past twelve-month period – up 3.64%

After yesterday’s close, Shaw Communications’ market cap was at $10.81 billion.

Price to Earnings (P/E) ratio was at 24.19.

The stock has a dividend yield of 4.30%.

The stock is part of the Services sector, categorized under the CATV Systems industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486399

Free Post Earnings Research Report: UnitedHealth Group’s Revenue Grew 9.5%; EPS Soared 109.8%

By Active-Investors

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free earnings report on UnitedHealth Group Inc. (NYSE: UNH). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=UNH. The Company posted its financial results on January 16, 2018, for the fourth quarter fiscal 2017. UnitedHealth’s revenue and adjusted EPS surpassed analysts’ expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, UnitedHealth Group most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=UNH

Earnings Highlights and Summary

For three months ended December 31, 2017, UnitedHealth Group’s total revenues increased 9.5% to $52.06 billion from $47.54 billion in Q4 FY16. The Company’s total revenue surpassed analysts’ expectations of $51.52 billion.

UnitedHealth Group’s full year 2017 revenues grew 8.8% to $201.2 billion with revenue growth broad-based and balanced across the businesses, reflecting strong demand for the Company’s product and service offerings.

For the reported quarter, the Company’s operating income increased 24.8% to $3.98 billion from $3.19 billion in Q4 FY16. For the reported quarter, the Company’s operating margin increased 90 basis points to 7.6% of revenue from 6.7% of revenue in Q4 FY16.

During Q4 FY17, UnitedHealth Group’s earnings before tax (EBT) increased 25.7% to $3.67 billion from $2.92 billion in the same period last year. For the reported quarter, the Company’s EBT margin increased 90 basis points to 7% of revenue from 6.1% of revenue in Q4 FY16.

For the reported quarter, UnitedHealth Group’s net income increased 114.8% to $3.62 billion on a y-o-y basis from $1.68 billion in Q4 FY16. During Q4 FY17, the Company’s diluted EPS increased 109.8% to $3.65 on a y-o-y basis from $1.74 in the same period last year.

For the reported quarter, UnitedHealth Group’s adjusted net income increased 25.4% to $2.56 billion on a y-o-y basis from $2.04 billion in Q4 FY16. During Q4 FY17, the Company’s adjusted diluted EPS increased 22.7% to $2.59 on a y-o-y basis from $2.11 in the same period last year. Adjusted diluted EPS surpassed analysts’ expectations of $2.50.

UnitedHealth Group’s FY17 earnings from operations jumped 17.6% to $15.2 billion on a y-o-y basis, and adjusted net earnings advanced 25.1% to $10.07 per share.

UnitedHealth Group’s Segment Details

UnitedHealthcare – During Q4 FY17, the UnitedHealthcare segment’s revenue increased 9.6% to $41.60 billion from $37.95 billion in the same period last year. For the reported quarter, the segment’s operating margin increased 50 basis points to 4.2% of revenue from 3.7% of revenue in Q4 FY16.

Optum – During Q4 FY17, the Optum segment’s revenue increased 10% to $24.39 billion from $22.17 billion in the same period last year. For the reported quarter, the segment’s operating margin increased 100 basis points to 9.1% of revenue from 8.1% of revenue in Q4 FY16.

Balance Sheet

As on December 31, 2017, UnitedHealth Group’s cash and short-term investments increased 16.7% to $15.49 billion from $13.28 billion on December 31, 2016. For the reported quarter, the Company’s long-term debt, less current maturities increased 11.9% to $28.84 billion from $25.78 billion in Q4 FY16.

For the reported quarter, the Company’s net accounts receivable increased 17.4% to $9.57 billion from $8.15 billion in Q4 FY16. For the reported quarter, the Company’s medical costs payable increased 9% to $17.87 billion from $16.39 billion in Q4 FY16.

During FY17, the Company’s net cash provided by operating activities increased 38.8% to $13.60 billion from $9.80 billion in FY16, and were 1.3 times net earnings, with an increasing mix of cash generated by non-insurance businesses in FY17.

Outlook

For FY18, the Company expects revenue to be in the range of $223.00 billion to $225.00 billion and operating margin to be in the band of 7.4% to 7.8% of revenue.

The Company estimates diluted EPS to be in the range of $11.65 to $11.95 and adjusted diluted EPS to be in the band of $12.30 to $12.60 for fiscal 2018.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, UnitedHealth Group’s stock climbed 1.98%, ending the trading session at $243.16.

Volume traded for the day: 6.23 million shares, which was above the 3-month average volume of 2.92 million shares.

Stock performance in the last month – up 9.62%; previous three-month period – up 19.26%; past twelve-month period – up 54.15%; and year-to-date – up 10.30%

After yesterday’s close, UnitedHealth Group’s market cap was at $235.38 billion.

Price to Earnings (P/E) ratio was at 27.63.

The stock has a dividend yield of 1.23%.

The stock is part of the Healthcare sector, categorized under the Health Care Plans industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486402

Blog Exposure – Trillium Announces Changes to Senior Management Team

By Active-Investors

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Trillium Therapeutics Inc. (NASDAQ: TRIL) (“Trillium”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TRIL as the Company’s latest news hit the wire. On January 17, 2018, the Company announced certain changes to its leadership team. The Company appointed Dr. Blythe Thomson as Executive Medical Director and Jane E. Cole as Senior Director, Clinical Operations. Dr. Brian E. Jahns was named Senior Vice President of Commercial and Business Development. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Trillium Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=TRIL

Eric Sievers Transitioned from Chief Medical Officer to Senior Clinical Advisor

Trillium made another change to its senior management team. Eric Sievers, MD, has transitioned from Chief Medical Officer to Senior Clinical Advisor. He will be responsible for maintaining a close association with the Company’s clinical programs and advisors, and continue to assist Trillium with clinical strategy and communications.

Dr. Sievers has served in several senior roles at Seattle Genetics, most recently as Senior Vice President, Clinical Development. At Seattle Genetics, he helped write and supervise pivotal trials that led to the US registration of ADCETRIS for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma in 2011. Dr. Sievers served as Medical Director at Zymogenetics from 2003 to 2006.

New Team to Have a Major Impact on Advancement of TTI-621 Program

Dr. Niclas Stiernholm, President and Chief Executive Officer (CEO) of Trillium, commented that these additions to the Company’s management team further bolster its planned pipeline development activities. The new team members bring diverse and deep drug development expertise, and will have a major impact on the advancement of the Company’s TTI-621 program and corporate growth.

Blythe Thomson’s Career Path

Dr. Blythe Thomson, a board certified pediatric hematologist/oncologist, has held multiple academic and industry appointments, most recently at Ariad Pharmaceuticals, Epizyme Inc. and Medpace. She brings a great depth of experience in all phases of clinical development of therapies for solid tumors and hematologic malignancies, and will oversee Trillium’s development programs, ensuring they are optimized for adaptability and efficiency. Dr. Thomson completed her medical training at Ohio State University and the Fred Hutchinson Cancer Research Center, University of Washington, and currently serves as an attending physician at Floating Hospital for Children, Tufts University School of Medicine.

Jane E. Cole’s Professional Achievements

Jane E. Cole brings to Trillium over 25 years of experience, leadership, and capability in the global execution of drug development programs. A registered nurse, Ms. Cole has led numerous development teams in executing Phase-I through Phase-IV clinical trials globally. She has previously held clinical operation roles at Hoffmann-La Roche, as well as in smaller biotechnology and contract research organizations. In her current role, she will oversee the Company’s clinical operations team and its relationships with clinical research organizations. Ms. Cole joins Trillium from Chiltern International, where she was Project Director, Global Executive Lead.

Brian E. Jahns’ Career History

Dr. Brian E. Jahns has an extensive background in the pharmaceutical and health care industry, most recently as Vice President Oncology and Vice President Product Strategy for Hoffmann-La Roche Canada. He has been involved in the success of products such as Rituxan®, Avastin®, Zelboraf®, and Herceptin®. Dr. Jahns will focus on developing partnership opportunities between Trillium and potential collaborators, and providing input on the Company’s commercialization activities. He completed his B.Sc. and Pharm.D. at Wayne State University, and conducted his post-doctoral studies at the University of Illinois at Chicago before serving on the faculty of the University of Toronto School of Pharmacy.

Trillium Made an Addition to its Board in October 2017

On October 11, 2017, the Company appointed Dr. Helen Tayton-Martin to its Board of Directors. Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has more than 25 years of experience working within the pharma, biotech, and consulting environment in disciplines across pre-clinical and clinical development, outsourcing, strategic planning, due diligence, and business development.

About Trillium Therapeutics Inc.

Founded in 2004, Trillium is a clinical stage immuno-oncology Company developing innovative therapies for the treatment of cancer. The Company’s lead program, TTI-621, is a SIRPaFc fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. Trillium is headquartered in Mississauga, Ontario.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, Trillium Therapeutics’ stock slightly advanced 0.92%, ending the trading session at $7.90.

Volume traded for the day: 107.20 thousand shares.

Stock performance in the last month – up 4.64%; previous three-month period – up 16.18%; past twelve-month period – up 44.95%; and year-to-date – up 8.97%

After yesterday’s close, Trillium Therapeutics’ market cap was at $85.28 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486401

Wired News – Amarin Initiates Clinical Development of VASCEPA in Mainland China

By Active-Investors

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. plc (NASDAQ: AMRN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AMRN as the Company’s latest news hit the wire. On January 17, 2018, the Company, a biopharmaceutical organization focused on the commercialization and development of therapeutics to improve cardiovascular health, declared that its partner Eddingpharm has initiated the clinical trial of Vascepa (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia (TG ≥500 mg/dL) in Mainland China, or China. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Amarin most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AMRN

About Vascepa

Amarin’s first FDA approved product, Vascepa, is a highly pure, omega-3 fatty acid, which is available by prescription. Vascepa capsules, known as AMR101 in scientific literature, are single-molecule prescription products that contain omega-3 acid EPA in ethyl-ester form. Vascepa is known to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels.

Although Vascepa is not fish oil, it is derived from fish through a stringent and complex FDA-regulated manufacturing process of eliminating impurities and isolating and protecting the single molecule active ingredient.

Amarin Signed Exclusive Agreement with Eddingpharm for Vascepa

On February 26, 2015, Amarin signed an exclusive agreement with Eddingpharm to develop and commercialize Vascepa in Mainland China, Hong Kong and Macao Special Administrative Regions, and Taiwan. As per the agreement, Eddingpharm is responsible for Vascepa’s development, regulatory activities, commercialization, and its associated costs.

Eddingpharm is a Chinese specialty pharmaceutical Company dedicated towards bringing high-quality medicines from all over the world to the Chinese healthcare market in order to provide patients with more treatment options and better healthcare opportunities. The Company has a strong footprint in top-tier cities of China, while it is growing rapidly in lower tier cities. It has over 17,000 hospitals and 15,000 pharmacies in 30 provinces with a sales force of over 1,000 professional personnel. Over the years, Eddingpharm has expanded its product portfolio through in-licensing, joint ventures, strategic alliances, exclusive distribution, and other forms of collaboration with multinational pharmaceutical Companies, specialty pharmaceutical Companies, and biotech Companies in the US and Europe.

Vascepa’s Success in MARINE Trial

The MARINE trial was a Phase-3, multi-center, placebo-controlled, randomized, double-blind, 12-week study that treated patients with severe (≥500 mg/dL) hypertriglyceridemia, more commonly known as very high triglycerides, or VHTG. It enrolled a total of 229 patients.

Amarin reported positive top-line results for the MARINE trial in November 2010, which met its primary and other key efficacy endpoints. The MARINE trial showed that Vascepa 4g/day considerably decreased triglyceride levels by 33% compared to placebo, without increasing LDL-C (non-significant decrease of 2% vs placebo). Moreover, Vascepa also exhibited a statistically significant decrease compared to placebo in multiple other important lipid biomarkers in MARINE, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), lipoprotein-phospholipase A2 (Lp-PLA2), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), and the inflammatory marker high-sensitivity C-reactive protein (hsCRP).

New Trial to Evaluate Vascepa in China

Eddingpharm intends to conduct a multi-center, placebo-controlled, randomized, double blind trial in China, similar to the MARINE trial conducted by Amarin. It would be a 12-week study on patients with severe hypertriglyceridemia, more commonly known as very high triglycerides, or VHTG. Its primary endpoint is the percentage change in triglyceride levels from baseline compared to placebo after 12 weeks of treatment. Eddingpharm expects this study to complete within the next two years.

This clinical trial could make Vascepa the first-ever pure prescription grade EPA-based drug product in China. However, its commercial opportunity in China is mostly based on the prevalence of hypertriglyceridemia in the country. It is estimated that hypertriglyceridemia affects approximately 17.7% of the adult Chinese population, which is about 185 million people.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, Amarin’s stock marginally dropped 0.50%, ending the trading session at $3.98.

Volume traded for the day: 1.29 million shares.

Stock performance in the last month – up 17.40%; previous three-month period – up 20.97%; and past twelve-month period – up 36.30%

After yesterday’s close, Amarin’s market cap was at $1.03 billion.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers – Other industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486405

Free Research Report as BlackRock’s Q4 Results Outshone Forecasts

By Active-Investors

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free earnings report on BlackRock, Inc. (NYSE: BLK). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLK. The Company posted its financial results on January 12, 2018, for the fourth quarter fiscal 2017 (Q4 FY17) and for the full fiscal year 2017 (FY17). The New York-based Company’s revenues and adjusted diluted EPS grew 20% and 21% y-o-y, respectively; outperforming market consensus forecasts. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BlackRock most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BLK

Earnings Highlights and Summary

During Q4 FY17, BlackRock’s total revenue was $3.47 billion compared to $2.89 billion in Q4 FY16, topping market consensus estimates of $3.35 billion. The Company’s y-o-y revenue growth was attributed to rises in base fees, performance fees, and technology and risk management revenue. Meanwhile, the Company’s revenue used for operating margin measurement rose to $3.33 billion for Q4 FY17, from $2.77 billion in the prior year’s same quarter.

The investment Company reported a GAAP net income of $2.30 billion, or $14.07 per diluted share, in Q4 FY17 compared to $851 million, or $5.13 per diluted share, in Q4 FY16. Furthermore, the Company’s adjusted net income increased to $1.02 billion, or $6.24 per diluted share, during the reported quarter from $852 million, or $5.14 per diluted share, in Q4 FY16. Wall Street had expected the Company to report an adjusted net income of $6.08 per diluted share.

BlackRock’s total revenue was $12.49 billion for the year ended December 31, 2017, up 12% from $11.16 billion in the prior year. The Company’s GAAP net income increased to $4.97 billion, or $30.23 per diluted share, during FY17 from $3.17 billion, or $19.04 per diluted share, in the last year. Additionally, the Company’s adjusted net income was $3.72 billion, or $22.60 per diluted share, for FY17 which came in above the $3.21 billion, or $19.29 per diluted share, posted in FY16.

Earnings Metrics

During the reported quarter, the Company reported total expenses of $1.98 billion compared to $1.67 billion in Q4 FY16. The Company reported an increase in employee compensation and benefits of $119 million y-o-y in Q4 FY17, primarily reflecting higher incentive compensation, driven by higher performance fees, higher operating income, and higher headcount. BlackRock’s general and administration (G&A) expenses also grew $93 million y-o-y in Q4 FY17, due to higher technology and occupancy expenses and professional services, as well as professional services fees. Meanwhile, the Company’s adjusted operating income grew to $1.49 billion, or 44.8% of total revenues, in Q4 FY17 from $1.23 billion, or 44.4% of total revenues, in the year ago comparable quarter.

BlackRock had assets under management amounting to $6.29 trillion as on December 31, 2017, compared to $5.15 trillion at the end on Q4 FY16. The Company reported total net flows of $102.93 billion in Q4 FY17 compared to $98.05 billion in Q4 FY16.

Business by Client Type

Retail – The long-term net inflows from Retail were $11.39 billion in Q4 FY17, which included net inflows of $7.40 billion from the United States and $4.0 billion internationally. The fixed income net inflows came in at $8.01 billion, led by net inflows into unconstrained, short duration, and municipals categories. Furthermore, multi-asset net inflows of $1.99 billion largely constituted of Multi-Asset Income fund family, paced by flows into international equities.

iShares ETFs – In Q4 FY17, iShares ETFs long-term net inflows stood at $54.80 billion, primarily attributable to strength in iShares Core, precision exposure, and financial instrument ETFs. The equity net inflows were $44.89 billion, whereas fixed income net inflows came in $8.67 billion. Furthermore, Commodities iShares generated $1.0 billion of net inflows during the reported quarter.

Institutional Active – Institutional Active long-term net inflows of $2.19 billion during Q4 FY17 were led by multi-asset net inflows of $2.91 billion and fixed income net inflows of $2.31 billion. However, there was equity net outflows of $1.24 billion in Q4 FY17 primarily because of fundamental active equities. Moreover, alternatives also reported net outflows of $1.80 billion, which consisted of $3.9 billion due to return of capital.

Institutional Index – BlackRock’s Institutional Index long-term net inflows were $12.20 billion in Q4 FY17, which included fixed income net inflows of $23.96 billion, driven by demand for liability-driven solutions. Meanwhile, the long-term net inflows were partially offset by equity net outflows of $9.01 billion.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, BlackRock’s stock slightly rose 0.47%, ending the trading session at $579.22.

Volume traded for the day: 819.78 thousand shares, which was above the 3-month average volume of 473.72 thousand shares.

Stock performance in the last month – up 13.16%; previous three-month period – up 21.80%; past twelve-month period – up 53.23%; and year-to-date – up 12.75%

After yesterday’s close, BlackRock’s market cap was at $92.08 billion.

Price to Earnings (P/E) ratio was at 27.12.

The stock has a dividend yield of 1.73%.

The stock is part of the Financial sector, categorized under the Asset Management industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486407

Free Post Earnings Research Report: Wells Fargo’s Revenue Grew 2.2%; EPS Surged 21%

By Active-Investors

Stock Monitor: First Republic Bank Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free earnings report on Wells Fargo & Co. (NYSE: WFC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=WFC. The Company posted its financial results on January 12, 2018, for the fourth quarter fiscal 2017. The Company’s EPS surpassed analysts’ expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for First Republic Bank (NYSE: FRC), which also belongs to the Financial sector as the Company Wells Fargo. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=FRC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Wells Fargo most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=WFC

Earnings Highlights and Summary

For three months ended December 31, 2017, Wells Fargo’s revenues increased 2.2% to $22.05 billion from $21.58 billion in Q4 FY16. The Company’s revenue was below analysts’ expectations of $22.38 billion.

For the reported quarter, the Company’s total interest income increased 6% to $14.96 billion from $14.06 billion in Q4 FY16. For the reported quarter, the Company’s total interest expense increased 60% to $2.65 billion from $1.66 billion in Q4 FY16. For the reported quarter, the Company’s net interest income decreased 1% to $12.31 billion from $12.40 billion in Q4 FY16.

During Q4 FY17, the Company’s net interest margin was 2.84% compared to 2.87% in the fourth quarter of 2016.

For the reported quarter, the Company’s total non-interest income increased 6% to $9.74 billion from $9.18 billion in Q4 FY16. For the reported quarter, the Company’s salaries expense increased 5% to $4.40 billion from $4.19 billion in Q4 FY16. For the reported quarter, the Company’s employee benefits expense increased 17% to $1.29 billion from $1.10 billion in Q4 FY16. For the reported quarter, the Company’s total non-interest expense increased 27% to $16.80 billion from $13.22 billion in Q4 FY16.

During Q4 FY17, Wells Fargo’s earnings before tax (EBT) decreased 39% to $4.60 billion from $7.56 billion in the same period last year.

For the reported quarter, Wells Fargo’s net income increased 18% to $5.74 billion on a y-o-y basis from $4.87 billion in Q4 FY16. During Q4 FY17, the Company’s diluted EPS increased 21% to $1.16 on a y-o-y basis from $0.96 in the same period last year. Diluted EPS surpassed analysts’ expectations of $1.07.

Asset Quality

During Q4 FY17, Wells Fargo’s non-performing assets decreased 23.6% to $8.68 billion from $11.36 billion in the same period last year. For the reported quarter, the Company’s non-performing assets to total loans ratio was 0.91% compared to 1.17% in Q4 FY16.

For the reported quarter, the Company’s allowance for credit losses to total loans ratio was 1.25% compared to 1.30% in Q4 FY16.

Wells Fargo’s Segment Details

Community Banking – During Q4 FY17, the Company’s community banking segment’s net interest income decreased 0.3% to $7.54 billion from $7.56 billion in the same period last year. For the reported quarter, the segment’s non-interest income increased 9.4% to $4.49 billion from $4.11 billion in Q4 FY16. For the reported quarter, the segment’s net income surged 34.4% to $3.67 billion from $2.73 billion in Q4 FY16.

Wholesale Banking – During Q4 FY17, the wholesale banking segment’s net interest income decreased 2.6% to $4.21 billion from $4.32 billion in the same period last year. For the reported quarter, the segment’s non-interest income increased 1.9% to $2.88 billion from $2.83 billion in Q4 FY16. For the reported quarter, the segment’s net income decreased 2.1% to $2.15 billion from $2.19 billion in Q4 FY16.

Wealth and Investment Management – During Q4 FY17, the wealth and investment management segment’s net interest income increased 6.8% to $1.13 billion from $1.06 billion in the same period last year. For the reported quarter, the segment’s non-interest income increased 5.3% to $3.17 billion from $3.01 billion in Q4 FY16. For the reported quarter, the segment’s net income increased 0.9% to $659 million from $653 million in Q4 FY16.

Balance Sheet

As on December 31, 2017, Wells Fargo’s cash and due from banks increased 13% to $23.37 billion from $20.73 billion on December 31, 2016. For the reported quarter, the Company’s long-term debt decreased 12% to $225.02 billion from $255.08 billion in Q4 FY16.

For the reported quarter, the Company’s loans decreased 1% to $956.77 billion from $967.70 billion in the fourth quarter of 2016. For the reported quarter, the Company’s total deposits increased 2% to $1.34 trillion from $1.31 trillion in Q4 FY16.

For the reported quarter, the Company’s book value per share was $37.44 compared to $36.92 in Q4 FY16. For the reported quarter, the Company’s tangible book value per share was $31.43 compared to $30.99 in Q4 FY16.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, Wells Fargo’s stock marginally climbed 0.11%, ending the trading session at $63.95.

Volume traded for the day: 15.94 million shares.

Stock performance in the last month – up 6.81%; previous three-month period – up 20.23%; past twelve-month period – up 17.84%; and year-to-date – up 5.41%

After yesterday’s close, Wells Fargo’s market cap was at $316.46 billion.

Price to Earnings (P/E) ratio was at 16.54.

The stock has a dividend yield of 2.44%.

The stock is part of the Financial sector, categorized under the Money Center Banks industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486403

Free Post Earnings Research Report: ADTRAN Reported Better Than Expected Results

By Active-Investors

Stock Monitor: Optical Cable Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 19, 2018 / Active-Investors.com has just released a free earnings report on ADTRAN, Inc. (NASDAQ: ADTN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADTN. The Company posted its financial results on January 16, 2018, for the fourth quarter fiscal 2017. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Optical Cable Corporation (NASDAQ: OCC), which also belongs to the Technology sector as the Company ADTRAN. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=OCC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ADTRAN most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ADTN

Earnings Highlights and Summary

For three months ended December 31, 2017, ADTRAN’s total revenues decreased 22.4% to $126.52 million from $162.99 million in Q4 FY16. The Company’s total revenue surpassed analysts’ expectations of $125.03 million.

For the reported quarter, the Company’s gross profit was $58.81 million compared to $70.79 million in Q4 FY16. For the reported quarter, the Company’s gross margin increased 310 basis points to 46.5% of revenue from 43.4% of revenue in Q4 FY16.

During Q4 FY17, ADTRAN’s selling, general, and administrative (SG&A) expenses decreased 8.9% to $31.39 million from $34.44 million in the same period last year. For the reported quarter, the Company’s research and development (R&D) expenses decreased 1.8% to $31.49 million from $32.08 million in Q4 FY16.

For the reported quarter, the Company’s operating loss was $4.07 million compared to operating income of $4.27 million in Q4 FY16.

During Q4 FY17, ADTRAN’s earnings before tax (EBT) was negative $741,000 compared to positive $6.84 million in the same period last year.

For the reported quarter, ADTRAN’s net loss was $11.12 million compared to net income of $7.57 million in Q4 FY16. During Q4 FY17, the Company’s diluted EPS was negative $0.23 compared to positive $0.16 in the same period last year. During Q4 FY17, the Company’s adjusted diluted EPS decreased 76.2% to $0.05 from $0.21 in the same period last year. Adjusted diluted EPS surpassed analysts’ expectations of negative $0.04.

ADTRAN’s Segment Details

Products – During Q4 FY17, the Products segment’s revenue decreased 24.2% to $96.06 million from $126.79 million in the same period last year. For the reported quarter, the segment’s gross profit decreased 21.4% to $46.36 million from $59.00 million in Q4 FY16.

Services – During Q4 FY17, the Services segment’s revenue decreased 15.8% to $30.46 million from $36.19 million in the same period last year. For the reported quarter, the segment’s gross profit increased 5.7% to $12.45 million from $11.78 million in Q4 FY16.

Balance Sheet

As on December 31, 2017, ADTRAN’s cash and cash equivalents increased 8.2% to $86.43 million from $79.90 million on December 31, 2016.

For the reported quarter, the Company’s net accounts receivable increased 55.8% to $143.84 million from $92.35 million in Q4 FY16. For the reported quarter, the Company’s accounts payable decreased 21.8% to $60.50 million from $77.34 million in Q4 FY16.

For the reported quarter, the Company’s net inventory increased 16.6% to $122.54 million from $105.12 million in Q4 FY16. For the reported quarter, the Company’s total assets decreased 0.3% to $665.01 million from $667.24 million in Q4 FY16.

During FY17, the Company’s net cash provided by operating activities was negative $42.37 million compared to positive $42.00 million in FY16.

On January 16, 2018, the Company’s Board of Directors declared a cash dividend of $0.09 per common share, payable on February 14, 2018, to holders of record at the close of business on January 31, 2018.

Stock Performance Snapshot

January 18, 2018 – At Thursday’s closing bell, ADTRAN’s stock tumbled 11.54%, ending the trading session at $16.67.

Volume traded for the day: 2.07 million shares, which was above the 3-month average volume of 409.66 thousand shares.

After yesterday’s close, ADTRAN’s market cap was at $800.90 million.

Price to Earnings (P/E) ratio was at 19.06.

The stock has a dividend yield of 2.16%.

The stock is part of the Technology sector, categorized under the Communication Equipment industry. This sector was up 0.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 486404